Skip to main content
. Author manuscript; available in PMC: 2015 Jun 5.
Published in final edited form as: Am J Psychiatry. 2015 Jan 13;172(4):373–382. doi: 10.1176/appi.ajp.2014.14010123

Table 2.

CA1 concentrations of GluN2B-containing NMDA receptor, PSD95 and GAD protein. Group average +/− standard error of the mean

The CA1 concentrations of the three target proteins altered in CA3. In CA1 tissue, GluN2B-containing NMDA receptor, PSD95, or GAD67 were not altered in SZ, in either the whole cohort or in the off medication SZ cohort subgroup; primary comparisons were not significant with the bonferroni correction.

PROTEIN HC(all) SEM(±) SZ(all) SEM(±) p HC(*) SEM(±) SZ(OFF) SEM(±) p
GluN2B/GluN1 0.56 0.08 0.65 0.09 0.34 0.64 0.11 0.64 0.08 0.99
PSD95 1.46 0.23 2.05 0.16 0.084 1.75 0.37 1.91 0.22 0.72
GAD67 0.86 0.04 0.83 0.04 0.70 0.88 0.05 0.79 0.08 0.31
*

these HC are the subgroup of HC paired with the SZ off medication cases.

**

HC(all), N= 21; SZ(all), N=21; HC(*), N=11; SZ(off), N=11

HHS Vulnerability Disclosure